CSIMarket



Quest Diagnostics Inc  (DGX)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare

Quest Diagnostics Inc's ROA per quarter

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


Return On Assets (Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Total Assets Change 3.51 % -3.51 % -2.96 % -4.04 % -0.99 %
Y / Y Net Income Change -61.54 % -23.88 % -32.18 % -10.83 % 236.79 %
Net Income (TTM) in Millions 1,563 1,963 2,080 2,276 2,340
Return On Assets (TTM) 11.59 % 14.68 % 15.41 % 16.74 % 17.03 %
Total Ranking # 635 # 475 # 491 # 366 # 332
Total Assets (TTM) in Millions 13,312 13,442 13,611 13,572 12,861
Seq. Total Assets Change -0.97 % -1.24 % 0.29 % 5.53 % -7.68 %
Seq. Net Income Change -32.98 % -9.69 % -21.63 % -18.92 % 32.65 %


Roa Comment
Quest Diagnostics Inc yielded Return on Asset in II. Quarter above company average, at 11.59 %.

Return on assets decreased compare to previous quarter, due to detoriation of net income.

Within Healthcare sector 87 other companies have achieved higher return on assets. While Return on assets total ranking has deteriorated compare to previous quarter from 475 to 635.

What is ROA?
Return On Assets Company Ranking
Within: No.
Industry # 4
Sector # 88
Overall # 633

Return On Assets Statistics
High Average Low
17.03 %
8.52 %
4.28 %
(Jun 30 2021)   (Dec. 31, 2007)


Financial Statements
Quest Diagnostics Inc's Assets $ 13,312 Millions DGX's Balance sheet
Quest Diagnostics Inc's Income $ 250 Millions Quarterly DGX's Income Statement
DGX's Income by Division See DGX's Income by Division



Annual Return On Assets (Dec 31 2021)
FY 2021
(Dec 31 2020)
FY 2020
(Dec 31 2019)
FY 2019
(Dec 31 2018)
FY 2018
(Dec 31 2017)
FY 2017
Y / Y Total Assets Change -2.96 % 9.21 % 16.72 % 4.76 % 3.99 %
Total Assets in Millions 13,611 14,026 12,843 11,003 10,503
Y / Y Net Income Change 38.76 % 65.45 % 14.97 % -4.37 % 18.39 %
Net Income in Millions 2,080 1,499 906 788 824
Return On Assets 15.28 % 10.69 % 7.05 % 7.16 % 7.85 %




Roa Comment
In the fiscal year 2021 ROA improved to 15.28 % compare to previous year, due to annual net income growth of 38.76 % to $2,080.00 millions, and due to decline of value in Quest Diagnostics Inc's assets by -2.96 % to $13,611.00 millions, compare to $13,611.00 a year before.


More Return On Equity Ratios
Medical Laboratories Industry Return On Asstes Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DGX's Roa Ratio versus Medical Laboratories Industry, Healthcare Sector and overall Market
Highest Ranking Return On Asstes
Lowest Ranking Return On Asstes
Roa for DGX's Competitors
Roa for Quest Diagnostics Inc's Suppliers
Return On Asstes for DGX's Customers

You may also want to know
DGX's Roi DGX's Inventory Turnover Ratio DGX's Growth Rates DGX's Dividend Comparisons
DGX's Profitability Ratios DGX's Asset Turnover Ratio DGX's Dividend Growth
DGX's Roe DGX's Valuation Ratios DGX's Financial Strength Ratios DGX's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2022, within Healthcare Sector ROA
Chemomab Therapeutics Ltd.  30.98 %
Oncotelic Therapeutics Inc.  30.93 %
Prophase Labs Inc.  29.54 %
Fulgent Genetics Inc.  28.87 %
Harpoon Therapeutics Inc.  28.57 %
Maravai Lifesciences Holdings Inc.  28.03 %
Exelixis Inc.  27.94 %
Halozyme Therapeutics Inc.  27.35 %
Idexx Laboratories Inc  26.50 %
Mettler Toledo International Inc  24.82 %
Quidelortho Corp  24.47 %
Semler Scientific inc.  24.39 %
National Research Corporation  23.98 %
Oramed Pharmaceuticals Inc.  23.77 %
Lftd Partners Inc.  23.70 %
Dynavax Technologies Corporation  22.89 %
Vertex Pharmaceuticals Inc  22.86 %
Corcept Therapeutics Inc  22.84 %
Catalyst Pharmaceuticals Inc.  22.35 %
Regeneron Pharmaceuticals Inc.  22.16 %
Journey Medical Corporation  21.56 %
West Pharmaceutical Services Inc.  20.91 %
Innoviva Inc.  20.45 %
Chemed Corporation  19.91 %
Incyte Corp  19.38 %
Selecta Biosciences Inc  19.20 %
Avalo Therapeutics Inc.  19.16 %
Co diagnostics Inc.  18.75 %
Elite Pharmaceuticals Inc.  18.69 %
Edwards Lifesciences Corporation  17.37 %



       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

GTBP's Profile

Stock Price

GTBP's Financials

Business Description

Fundamentals

Charts & Quotes

GTBP's News

Suppliers

GTBP's Competitors

Customers & Markets

Economic Indicators

GTBP's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071